Back

Early initiation of PCSK9 inhibitors in acute STEMI: Interim results of safety and efficacy from the EARLY-STEMI trial

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in acute coronary syndromes (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mohammed Thamer Ali

HMC Heart Hospital, Doha (Qatar)

4 More presentations in this session

Presentation thumbnail
Impact of beta-blocker Nebivolol versus Carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents
Doctor M. Susanti (Jawa Timur, ID)
Abstract Slides Video
Presentation thumbnail
Impact of Beta-Blocker Prescription at Discharge on Long-term Clinical Outcomes in ST elevation Myocardial Infarction Patients with Reduced LVEF treated with Drug-eluting Stents
Professor S. Park (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention and using direct oral anticoagulants
Mr O. Emilsson (Lund, SE)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of ticagrelor versus clopidogrel in acute myocardial infarction-associated cardiogenic shock: a propensity score-matched analysis
Doctor M. Presume (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in acute coronary syndromes (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Early TNF-alpha levels suppression by upstream evolocumab use in patients with acute myocardial infarction undergoing percutaneous coronary intervention
thumbnail
Congress Session
Novel pharmacological approaches in acute coronary syndromes
thumbnail
Congress Session
Late-breaking science on pharmacology

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources